XNAS · Healthcare · Biotechnology
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | Q3 2025 | -19.27 | -0.82 | +95.74% | $1.6M | ✅ Beat | — | — | — |
| 2025-08-12 | Q2 2025 | -2.62 | -3.12 | -19.08% | $765,000 | ❌ Miss | +33.83% | +57.78% | +48.40% |
| 2025-03-13 |
| Q4 2024 |
| -0.23 |
| -0.32 |
| -39.13% |
| $4.2M |
| ❌ Miss |
| -6.25% |
| +0.78% |
| -26.95% |
| 2024-08-07 | Q2 2024 | -0.28 | -0.31 | -10.71% | $4.1M | ❌ Miss | +8.11% | +4.96% | -1.80% |
| 2024-05-13 | Q1 2024 | -0.41 | -1.12 | -173.17% | $4.1M | ❌ Miss | +24.65% | +24.30% | +16.20% |
| 2024-03-06 | Q4 2023 | -0.45 | -0.53 | -17.78% | $2.9M | ❌ Miss | — | — | — |
| 2023-11-09 | Q3 2023 | -0.50 | -0.43 | +14.00% | $2.1M | ✅ Beat | +10.58% | +7.69% | +71.15% |
| 2023-08-02 | Q2 2023 | -0.50 | -0.47 | +6.00% | $880,000 | ✅ Beat | +0.22% | -4.02% | +12.95% |
Showing last 8 quarters.